Source link : https://newshealth.biz/health-news/me-too-cancer-drugs-not-often-compared-to-original/
TOPLINE: In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their first-in-class counterparts. And in these head-to-head RCTs, only 22% of the “me-too” agents showed a survival benefit compared to the originals. METHODOLOGY: Next-in-class, or […]
The post Me-Too Cancer Drugs Not Often Compared to Original first appeared on News Health.
—-
Author : News Health
Publish date : 2025-07-31 05:25:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8